CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.
CAR-T Cell Therapy: What We Never Dreamed Of
March 11th 2018Never in their wildest dreams dreams would immunologists from the last generation have imagined chimeric antigen receptor (CAR)-T cell therapy coming to light. The very notion of genetically engineering a T cell to recognize a tumor antigen would have been viewed almost as a pipe dream.
Late Effects Burden Lymphoma Survivors After Multimodality Treatment
February 28th 2018Many patients with lymphoma need treatment with both chemotherapy and radiation, but these treatments may be accompanied by significant late-term effects, according to a new study presented during the 2018 American Society of Clinical Oncology Cancer Survivorship Symposium.
Childhood Pneumonia May Be Associated With Cancer Risk
February 2nd 2018While causes for pneumonia were varied – including bacteria (14 percent), virus (22 percent) and unspecified (64 percent) – the majority of children did not have immune deficiencies recorded at the time of their pneumonia diagnosis.
Lymphoma Expert Suggests Asking About Clinical Trials Soon After Diagnosis
January 22nd 2018Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.
CAR-T Cell Therapy Gets Priority Review for Lymphoma Treatment
January 17th 2018The Food and Drug Administration granted a priority review to a supplemental biologics license application for Kymriah (tisagenlecleucel) to be used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who either relapse or are not eligible for an autologous stem cell transplant.
Adcetris Combination Granted Priority Review for Hodgkin Lymphoma Treatment
January 3rd 2018Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontline setting, according to Seattle Genetics, the company developing the drug.
Complications of Cancer: Nausea
December 20th 2017Of every complication caused from cancer and its treatments, nausea has been the worst for my sister. It has caused pain, discomfort and was the number one reason she returned to the emergency room. No matter what medications were dosed, whether it was orally or by IV, or how much they gave to her, so often, nothing ever seemed to work.